NCT06627530 - COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | Biotech Hunter

Enrollment

144

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions

Prostate Cancer

Interventions

DRUG

Darolutamide Oral Tablet

darolutamide 600 mg PO BID for 24 weeks

DRUG

leuprorelin

leuprorelin depot 22.5 mg SC every 12 weeks

Trial Locations (6)

RECRUITING

Santa Casa de Misericórdia de Feira de Santana, Feira de Santana

RECRUITING

Hospital Ophir Loyola, Belém

ACTIVE_NOT_RECRUITING

Hospital São Marcos, Teresina

RECRUITING

Hospital de Clínicas Ijuí, Ijuí

RECRUITING

Hospital Universitário Pedro Ernesto, Rio de Janeiro

RECRUITING

BP - A Beneficência Portuguesa de São Paulo, São Paulo